Impact of clinical features, cytogenetics, genetic mutations, and methylation dynamics of CDKN2B and DLC-1 promoters on treatment response to azacitidine

1. Martín, I.
2. Navarro, B.
3. Serrano, A.
4. Villamón, E.
5. Calabuig, M.
6. Solano, C.
7. Chaves, F.J.
8. Yagüe, N.
9. Orts, M.
10. Amat, P.
11. Fuentes, A.
12. Seda, E.
13. García, F.
14. Hernández-Boluda, J.C.
15. Tormo, M.